Affiliation: Boston University School of Medicine
- Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanomaOmar Eton
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, USA
J Transl Med 8:9. 2010..We sought to investigate the feasibility, safety, and antitumor activity of HSPPC-96 vaccines prepared from tumor specimens of patients with metastatic melanoma...
- A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim
Department of Melanoma Medical Oncology, M D Anderson Cancer Center, The University of Texas, Houston 77030, Texas, USA
Melanoma Res 19:42-9. 2009..86 and 0.45, respectively) between the two groups. Biochemotherapy is not more effective than IFN as adjuvant therapy for melanoma. These findings support early termination of this trial...
- Pilot study of high-dose, concurrent biochemotherapy for advanced melanomaKevin B Kim
Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 101:596-603. 2004..In the current study, the authors addressed the feasibility of increasing the doses of agents used in concurrent biochemotherapy...
- Biochemotherapy in patients with metastatic anorectal mucosal melanomaKevin B Kim
Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas 77030, USA
Cancer 100:1478-83. 2004..Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported...
- Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatmentCindy S Hwang
School of Medicine, Baylor College of Medicine, Houston, Texas, USA
Melanoma Res 18:241-5. 2008..A better understanding of the AKT and mitogen-activated protein kinase pathways is needed to optimize the clinical benefit of targeted therapy, such as imatinib...
- Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanomaAgop Y Bedikian
Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 430, Houston, Texas, USA
Melanoma Res 14:63-6. 2004..No grade 3 acute allergic reactions were observed. Paclitaxel given by short intravenous infusion is marginally active against previously treated non-choroidal melanoma...
- Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanomaOmar Eton
Department of Melanoma Sarcoma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 95:127-34. 2002..This study sought to determine the maximum tolerated dose (MTD) of IL-2 administered once daily by the SC route...
- Phase II evaluation of temozolomide in metastatic choroidal melanomaAgop Y Bedikian
The University of Texas M D Anderson Cancer Center, Department of Melanoma Medical Oncology, Houston, Texas 77030, USA
Melanoma Res 13:303-6. 2003..The treatments were well tolerated. We conclude that, like DTIC, temozolomide at the dose and schedule studied in this trial is not effective for the control of metastatic melanoma of uveal origin...
- Chemotherapy, cytokines, and biochemotherapy for melanomaOmar Eton
Department of Melanoma, Division of Cancer Medicine, Univerity of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Chemother Biol Response Modif 22:739-48. 2005
- Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec)Doina Ivan
Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Cutan Pathol 33:280-5. 2006..Gleevec, a novel class of anti-tumor drugs, may have a potential therapeutic benefit in melanoma, which involves abnormal activation of abl, c-kit, and platelet-derived growth factor (PDGF) tyrosine kinases...
- Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trialOmar Eton
Department Melanoma Sarcoma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:2045-52. 2002..In this phase III trial, we compared the effects of chemotherapy (cisplatin, vinblastine, and dacarbazine [CVD]) with those of sequential biochemotherapy consisting of CVD plus interleukin-2 and interferon alfa-2b...
- Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivoEric C McGary
Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, 77054, USA
J Invest Dermatol 122:400-5. 2004..Our data demonstrated that imatinib mesylate blocked both PDGFR-alpha and PDGFR-beta in vivo. It did not, however, affect the growth of melanoma cells expressing PDGFR, regardless of whether the cells expressed c-Kit...
- Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanomaJulie A Ellerhorst
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
Anticancer Drugs 13:169-72. 2002..We conclude that, in keeping with the general chemoresistance of melanoma, 9-NC at the dose and schedule studied in this trial is significantly toxic and is not active for metastatic melanoma of cutaneous or uveal origin...